Abstract
The development of cancer is a multistage process. The activation of proto-oncogenes and the inactivation of tumor suppressor genes play a critical role in the induction of tumors. Using human cell model systems of carcinogenesis, we have studied how oncogenes, tumor suppressor genes, and recessive cancer susceptibility genes participate in this multistep process. Normal human cells are resistant to the transforming potential of oncogenes, such as ras oncogenes, which are activated by specific point mutations. Since as many as 40% of some tumor types contain activated ras oncogenes, a preneoplastic transition in multistage carcinogenesis must involve changing from an oncogene-resistant stage to an oncogene-susceptible stage. The analysis of such critical steps in carcinogenesis using rodent systems has usually not represented the human disease with fidelity. In order to study this carcinogenic process, we have developed human cell, in vitro systems that represent some of the genetic changes that occur in cellular genes during human carcinogenesis. Using these systems, we have learned some of the functions of dominant activated-transforming oncogenes, tumor suppressor genes, and cellular immortalization genes and how they influence the carcinogenic process in human cells. Using our understanding of these processes, we are attempting to clone critical genes involved in the etiology of familial cancers. These investigations may help us to develop procedures that allow us to predict, in these cancer families, which individuals are at high risk for developing cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fould, L: The natural history of cancer. J Chronic Dis 8: 2–37, 1958
Nowell, P: The clonal evolution of tumor cell populations. Science 194: 23–28, 1976
Peto, R: Epidemiology, multistage models and short term mutagenesis tests. In: Origins of Human Cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1977, pp. 1403–1428
Foulds, L: Neoplastic development. Vol. I Academic Press, London, 1959
Farber, E, Cameron, R: The sequential analysis of cancer development. Adv Cancer Res 31: 125–226, 1980
Bishop, JM: Retroviruses. Annu Rev Biochem 47: 35–88, 1978
Chang, E, Furth, M, Scolnick, E, Lowy, D: Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479–483, 1982
Parada, LF, Tabin, CJ, Shih, C, Weinberg, RA: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297: 474–478, 1982
Santos, E, Tronick, SR, Aaronson, SA, Pulciani, S, Barbacid, M: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BLLB- and Harvey-MSV transforming genes. Nature 298: 343–345, 1982
Levine, AS: Fruit flies, yeast and one gene: development biology and cancer research come together. Med Pediatr Oncol 12: 357–374, 1984
Muller, R, Slamon, DJ, Tremblay, JM, Cline, MJ, Verma, IM: Differential expression and postnatal development of the mouse. Nature 299: 640–644, 1982
Goyette, M, Petropoulos, CJ, Shank, PR, Fanso, N: Expression of a cellular oncogene during liver regeneration. Science 219: 510–512, 1983
Klein, G, Klein, E: Evolution of tumor and impact of molecular oncology. Nature 315: 190–195, 1985
Waterfied, MD, Scare, GT, Whittle, N: Platelet derived growth factor is structurally related to the putative transforming protein p28 sis of Simian sarcoma virus. Nature 304: 35–39, 1983
Downward, J, Yarden, Y, Mayes, E: Close similarity of epidermal growth factor receptor and v-erb-8 oncogene protein sequence. Nature 137: 521–527, 1984
Sherr, CJ, Rettenmier, CW, Sacca, R, Roussel, MF, Look, AT, Stanley, ER: The c-fms proto-oncogene product is related to the mononuclear phagocyte growth factor, CSF-1. Cell 41: 665–676, 1985
Donner, P, Freiser_Wilke, I, Moelling, K: Nuclear localization and DNA binding of the transforming gene product of avian myelocytomatosis virus. Nature 296: 262–264, 1982
Kelly, K, Cochran, BH, Stiles, CD, Leder, P: Cell-specific regulation of the c-myc gene by lymphocyte mitogen and platelet derived growth factor. Cell 35: 603–610, 1983
Kruijer, W, Cooper, JA, Hunter, T, Verma, IM: Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. Nature 312: 711–720, 1984
Quantin, B, Breathnach, R: Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts. Nature 334: 538–539, 1988
Sagata, N, Daar, J, Oskarsson, M, Shonulter, SD, VandeWoude, GF: The product of the mos proto-oncogene as a candidate “initiator’ for oocyte maturation. Science 245: 643–646, 1989
Land, H, Parada, LF, Weinberg, RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596–602, 1983
Ruley, HE: Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304: 602–606, 1983
Adams, JM, Harris, AW, Pinkert, CA, Corcoran, LM, Alexander, WS, Cory, S, Palmiter, RD, Brinster, RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533–538, 1986
Knudson, AG, Strong, LC: Mutation and cancer: A model for Wilms' tumor of the kidney. J Natl Cancer Inst 48: 313–324, 1972
Harris, H, Klein, G: Malignancy of somatic cell hybrids. Nature 224: 1314–1316, 1969
Benedict, WF, Weissman, BE, Mark, C, Stanbridge, EJ: Tumorigenicity of human HT-1080 fibrosarcoma X normal fibroblast hybrids is chromosome dosage dependent. Cancer Res 34: 3471–3479, 1984
Weissman, BE, Sacon, PJ, Pasquale, SR, Jones, GR, Geiser, AG, Stanbridge, EJ: Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science 236: 175–180, 1987
Saxon, PJ, Srivatsan, ES, Stanbridge, EJ: Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 13: 3461–3466, 1986.
Seemayer, TA, Cavenee, WK: Biology of disease: molecular mechanism of oncogenesis. Laboratory Investigation 60: 5, 585–598, 1989
Cavenee, WK, Dryja, TP, Phillips, RA, Benedict, WF, Godbout, R, Gallie, BL, Murphree, AL, Strong, LC, White, RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779, 1983
Noda, M, Selinger, Z, Scolnick, EM, Bassin, RH: Flat revertants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes. Proc Natl Acad Sci USA 80: 5602–5606, 1983
Noda, M, Kitayama, H, Matsuzuki, T, Sugimoto, Y, Okayama, H, Bassin, R, Ikawa, Y: Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc Natl Acad Sci USA 86: 162–166, 1989
Schaefer, R, Iyer, J, Iten, E, Nirkko, AC: Partial reversion of the transformed phenotype in H-ras-transfected tumorigenic cells by transfer of a human gene. Proc Natl Acad Sci USA 85: 1590–1594, 1988
Tainsky, MA, Krizman, DB, Chiao, PJ, Yim, SO, Giovanella, BC: PA-1, a human cell model for multistage carcinogenesis: Oncogenes and other factors. Anticancer Res 8: 899–914, 1988
Olsen, E, Spizy, G, Tainsky, MA: Expression of oncogenic forms of N-ras or H-ras prevents skeletal muscle differentiation. Mol Cell Biol 7: 2104–2111, 1987
Fiszman, MY, Fuchs, P: Temperature-sensitive expression of differentiation in transformed myoblasts. Nature 254: 429–431, 1975
Pacifici, M, Boettiger, D, Roby, K, Holtzer, H: Transformation of chondroblasts by Rous sarcoma virus and synthesis of the sulfated proteoglycan matrix. Cell 11: 891–898, 1977
Boettiger, D, Roby, K, Brumbaugh, J, Biehl, J, Holtzer, H: Transformation of chicken embryo retinal melanoblasts by a temperature-sensitive mutant of Rous sarcoma virus. Cell 11: 881–890, 1977
Mintz, B, Fleischman, RA: Teratocarcinoma and other neoplasms as developmental defects in gene expression. Adv Cancer Res 34: 211, 1981
Huang, HS, Yee, J, Shew, J, Chen, P, Bookstein, R, Friedmann, T, Lee, E, Lee, W: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563–1566, 1988
DeCaprio, JA, Ludlow, JW, Lynch, D, Furukawa, Y, Griffin, J, Piwnica-Worms, H, Huang, CM, Livingston, DM: The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 58: 1085–1095, 1989
Buchkovich, K, Duffy, LA, Harlow, E: The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58: 1097–1105, 1989
DeCaprio, J, Ludlow, JW, Figge, J, Shew, J, Huang, C, Lee, W, Marsilio, E, Paucha, E, Livingston, DM: SV40 large antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54: 275–283, 1988
Ludlow, J, DeCaprio, JA, Huang, C, Lee, W, Paucha, E, Livingston, DM: SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 56: 57–65, 1989
Whyte, P, Buchkovich, KJ, Horowitz, JM, Friend, SH, Raybuck, M, Weinberg, RA, Harlow, E: Association between an oncogene and an antioncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334: 124–129, 1988
Parada, LF, Tabin, CJ, Shih, C, Weinberg, RA: Cooperation between gene encoding P53 tumor antigen and ras in cellular transformation. Nature 312: 649–651, 1984
Eliyahu, D, Raz, A, Gruss, P, Givol, D, Oren, M: Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature 312: 646–649, 1984
Finlay, CA, Hinds, PW, Levine, AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083–1093, 1989
Chen, P, Scully, P, Shew, J, Wang, JYJ, Lee, W: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58: 1193–1198, 1989
Rootman, J, Carruthers, JDA, Miller, RR: Retinoblastoma. Perspec Pediatr Pathol 10: 208, 1987
Lee, WH, Murphree, AL, Benedict, WF: Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 309: 458–460, 1984
Barbacid, M: Ras genes. Annu Rev Biochem 56: 779–827, 1987
Trahey, M, McCormick, F: Acytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238: 542–545, 1987
Cales, C, Hancock, JF, Marshall, CJ, Hall, A: The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product. Nature 332: 548–551, 1988
McCormick, F: ras GTPase activating protein: signal transmitter and signal terminator. Cell 56: 5–8, 1989
Shih, C, Weinberg, RA: Isolation of transforming activity in human bladder carcinoma cell line. Cell 29: 161–169, 1982
Krontiris, T, Cooper, GM: Transforming activity in human tumor DNAs. Proc Natl Acad Sci USA 78: 1181–1184, 1981
Bos, JL: ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689, 1989
Bos, JL, Fearon, ER, Hamilton, SR, Verlaan-de Vries, M, VanBoom, JH, Van derEb, AJ, Vogelstein, B: Prevalence of ras mutation in human colorectal cancers. Nature 327: 293–297, 1987
Vogelstein, B, Fearon, ER, Baker, SJ, Nigro, JM, Kern, SE, Hamilton, SR, Bos, J, Leppert, M, Nakamura, Y, White, R: Genetic alterations accumulate during colorectal tumorigenesis. In: Cavenee, W, Hastie, N, Stanbridge, E (eds) Recessive Oncogenes and Tumor Suppression. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 1989, pp 73–80
Rodenhuis, S, Van deWetering, ML, Mooi, WJ, Evers, SG, VanZandwijk, N, Bos, JL: Mutational activation of the K-ras oncogene, a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 37: 929–935, 1987
Rodenhuis, S, Slebos, RJC, Boot, AJM, Evers, SG, Mooi, WJ, Wagenaar, SS, VanBodgeom, PC, Bos, JL: K-ras oncogene activation in adenocarcinoma of the lung: incidence and possible clinical significance. Cancer Res 48: 5738–5741, 1988
Suda, Y, Aizawa, S, Hirai, S, Inoue, T, Furua, Y, Suzuki, M, Hirohashi, S, Ikawa, Y: Driven by the same Ig enhancer and SV40 T promoter ras induced lung adenomatous tumors, myc induced pre-B cell lymphomas and SV40 large T gene a variety of tumor in transgenic mice. EMBO J 6: 4055–4065, 1987
Albino, AP, LeStrange, R, Oliff, AL, Furth, ME, Old, LJ: Transforming ras genes from human melanomas; a manifestation of tumor heterogeneity? Nature 308: 69–72, 1984
Van 'tVeer, LJ, Burgering, BMTh, Versteeg, R, Boot, AJM, Ruiter, DJ, Osanto, S, Schrier, PI, Bos, JL: N-ras mutations in human cutaneous melanoma correlated with sun exposure. Mol Cell Biol 4: 3114–3116, 1989
Almoquera, C, Shibata, D, Forrester, K, Martin, J, Arnheim, N, Perucho, M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549–554, 1988
Lemoine, NR, Mayall, ES, Wyllie, FW, William, ED, Goyns, M, Stringer, B, Wynford-Thomas, D: High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4: 159–164, 1989
Needleman, SW, Kraus, MH, Srivastava, SK, Levine, PH, Aaronson, SA: High frequency of N-ras activation in acute myelogenous leukemia. Blood 67: 753–757, 1986
Farr, CJ, Saiki, RK, Ehrlich, HA, McCormick, F, Marshall, CJ: Analysis of ras gene mutations in acute myoloid leukemia using the polymorerase chain reaction and oligonucleotides. Proc Natl Acad Sci USA 48: 9228–9232, 1987
Padua, RA, Carter, G, Hughes, D, Gow, J, Farr, C, Oscier, D, McCormick, F, Jacobs, A: ras mutation in myelodysplasia detected by amplification, oligonucleotide hybridization and transformation. Leukemia (Baltimore) 2: 503–510, 1988
Senn, HP, Jiricny, J, Fopp, JM, Schmid, L, Moroni, C: Relapse cell population differs from acute onset clone as shown by absence of the initially activated N-ras oncogene in a patient with acute myelomonocytic leukemia. Blood 72: 931–935, 1988
Groce, CM, Nowell, PC: Molecular basis of human B cell neoplasia. Blood 65: 1–7, 1985
Taub, R, Moulding, C, Battey, J: Activation and somatic mutation of the translocated c-myc gene in Burkitt lymphoma cells. Cell 36: 339–348, 1984
Ahuja, H, Cline, MJ: Genetic and cytogenetic changes in acute lymphoblastic leukemia. Med Oncol Tumor Pharmacother 5: 211–222, 1988
Schwab, M, Alitalo, K, Klempnauer, KH: Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastomas. Nature 305: 245–248, 1983
Field, JK, Spandidos, DA, Stell, PM, Vaughan, ED, Evan, GI, Moore, JP: Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 4: 1463–1468, 1989
Cline, MJ: Oncogenes in hematologic neoplasia. Int J of Cell Cloning 7: 213–222, 1989
DeKlein, A, Geurts van Kessel, A, Grosveld, G, Bartram, CR, Hagemeijer, A, Bootsma, D, Spurr, NK, Heisterkamp, N, Groffen, J, Stephenson, JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300: 765–767, 1982
Heisterkamp, N, Stephenson, JR, Groffen, J, Hansen, PF, DeKlein, A, Bartram, CR, Grosveld, G: Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 306: 239–242, 1983
Konopka, JB, Watanable, SM, Witte, ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37: 1035–1042, 1984
Bargmann, CI, Hung, M-C, Weinberg, RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226–230, 1986
Bargmann, CI, Hung, M-C, Weinberg, RA: Multiple independent activation of the neu oncogene by a point mutation altering the transmembrane domain of P185. Cell 45: 649–657, 1986
Kraus, MH, Popescu, NC, Amsbaugh, SC: Overexpression of the EGF receptor-related proto-oncogene erb B-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605–610, 1987
Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987.
Varley, JM, Swallow, JE, Brammar, WJ: Alteration to either c-erb B-2 or c-myc proto-oncogenes in breast carcinoma correlates with poor short-term prognosis. Oncogene 1: 423–430, 1987
Der, CJ, Krontris, TG, Cooper, GM: Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79: 3637–3640, 1982
Der, CJ, Cooper, GM: altered gene products are associated with activation of cellular ras-K genes in human lung and colon carcinomas. Cell 32: 201–208, 1983
Goldfarb, MP, Shimizu, K, Perucho, M, Wigler, MH: Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296: 405–409, 1982
Hall, A, Marshall, CJ, Spurr, C, Weiss, RA: Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 303: 396–399, 1983
Shimizu, K, Goldfarb, M, Perucho, M, Wigler, MH: Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc Natl Acad Sci USA 80: 383–387, 1983
Reddy, EP, Reynolds, RK, Santos, E, Barbacid, M: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: 149–152, 1982
Tabin, CJ, Bradley, S, Bargmann, C, Weinberg, RA, Papageorge, A, Scolnick, E, Dhar, R, Lowy, D, Chang, E: Mechanism of activation of a human oncogene. Nature 300: 143–149, 1982
Taparowsky, EJ, Suard, Y, Fasano, O, Shimizu, K, Goldfarb, M, Wigler, MH: Activation of the T24 bladder carcinoma transforming gene is linked to a single amino-acid change. Nature 300: 762–768, 1982
Weinberg, RA: Oncogenes, antioncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 49: 3713–3721, 1989
Spandidos, DA, Wilkie, NM: Malignant transformation of early passage rodent cells by a single mutated oncogene. Nature 310: 469–475, 1983
Pozzatti, R, Muschel, R, Williams, J, Padmanabhan, R, Howard, B, Liotta, L, Khoury, G: Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials. Science 232: 223–227, 1986
Davenport E, Drobes S, Menke T, Vaidya, Taparowsky EJ: Cooperation of oncogenes in the multistep transformation of established fibroblasts in culture. Anticancer Res 8: 959–970
Herschman, HR, Brankow, DW: Ultraviolet irradiation transforms C3H10T1/2 cells to a unique, suppressible phenotype. Science 234: 1385–1388, 1986
Oshimura, M, Gilmer, TM, Barrett, JC: Nonrandom loss of chromosome 15 in Syrian hamster tumours induced by v-Ha-ras plus v-myc oncogenes. Nature 316: 636–639, 1985
Newbold, R, Overall, R: Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304: 648–651, 1983
Sager, R, Tanaka, K, Lau, CC, Ebina, Y, Anisowicz, A: Resistance of human cells to tumorigenesis induced by cloned transforming genes. Proc Natl Acad Sci USA 80: 7601–7605, 1983
Hurlin, PJ, Fry, DG, Maher, VM, McCormick, JJ: Morphological transformation, focus formation, and anchorage independent growth induced in diploid fibroblasts by expression of a transfected H-ras oncogene. Cancer Res 47: 5752–5757, 1987
Tainsky, MA, Shamanski, FL, Blair, DG, VandeWoude, GF: A human recipient cell for oncogene transfection studies. Mol Cell Biol 7: 1280–1284, 1987
Durst, M, Dzarlieva-Petrusevska, RT, Boukamp, P, Fusenig, NE, Gissmann, L: Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1: 251–256, 1987
Wilke, MS, Hsu, BM, Wille, JJJr, Pittelkow, MR, Scott, RE: Biologic mechanisms for the regulation of normal human keratinocyte proliferation and differentiation. Am J Pathol 131: 171–181, 1988
Zeuthen, J, Norgaard, JDR, Avner, P, Fellows, M, Wartiovaara, J, Vaheri, A, Rosen, J, Giovannella, BC: Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer 25: 19–32, 1980
Tainsky, MA, Shamanski, FL, Giovanella, BC, Blair, DG: A causal role for an activated ras in the tumorigenicity acquired by a human cell line. Cancer Res 47: 3235–3238, 1987
Tainsky, MA: Tumorigenic transformation of human teratocarcinoma cells by ras oncogenes but not the homologous proto-oncogenes. In: Colburn, NH, Moses, HL, Stanbridge, EJ, (eds). Growth Factors, Tumor Promoters and Cancer Genes. Proceedings of the UCLA Symposium on Molecular and Cellular Biology, New Series, Vol 58, Steamboat Springs, Alan R. Liss, Inc., New York, 1988, 58: 277–282
Tainsky, MA, Cooper, CS, Giovanella, BC, VandeWoude, GF: An activated ras N gene: Detected in late but not early passage human PA-1 teratocarcinoma cells. Science 225: 643–645, 1984
Berg, P, Southern, PJ: Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. Mol Appl Genet 1: 327–341, 1982
Santos, E, Tronick, SR, Aaronson, SA, Pulciani, S, Barbacid, M: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of Balb- and Harvey-MSV transforming genes. Nature 298: 343–345, 1982
Lautenberger, JA, Schulz, RA, Garon, CF, Tsichlis, PN, Papas, TS: Molecular cloning of avian myelocytomatosis virus (MC29) transforming sequence. Proc Natl Acad Sci USA 78: 1518–1522, 1981
Tainsky, MA, Krizman, DB, Chiao, PJ, Yim, SO, Giovanella, BC: PA-1, a human cell model for multistage carcinogenesis: oncogenes and other factors. Anticancer Res 8: 899–914, 1988
Krizman, DB, Giovanella, BC, Tainsky, MA: N-ras-mediated transformation requires a loss of a dominant transacting oncogene suppressor with antiproliferative activity. Somatic Cell and Mol Genetics 16: 115–127, 1990
Li, FP, Fraumeni, JFJr: Rhabdomyosarcoma in children: epidemiology study and identification of a familial cancer syndrome. JNCI 43: 1365–1373, 1969
Li, FP, Fraumeni, JFJr, Mulvihill, JJ, Blattner, WA, Dreyfus, MG, Tucker, MA, Miller, WR: A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358–5362, 1988
Strong, LC, Stine, M, Norsted, TL: Cancer in survivors of childhood soft tissue sarcoma and their relatives. JNCI 79: 1213–1220, 1987
Williams, WR, Strong, LC: Genetic epidemiology of soft tissue sarcomas in children. In: Familial Cancer, Weber and Muller, Eds, S. Karger, Basel, 1985, pp 151–153
McCormick, JJ, Maher, VM: Toward an understanding of the malignant transformation of diploid human fibroblasts. Mutat Res 199: 273–291, 1988
Hayflick, L: The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37: 614–624, 1965
Brodeur, GM, Green, AA, Hayes, FA, Williams, KJ, Williams, DL, Tsiatis, AA: Cytogenetic feature of human neuroblastomas and cell lines. Cancer Res 41: 4678–4683, 1981
Gilbert, F, Feder, M, Balaban, G, Brangman, D, Lurie, DK, Podolski, R, Rinaldt Vinikoor, N, Weisband, J: Human neuroblastomas and abnormalities of chromosome 1 and 17. Cancer Res 44: 5444–5450, 1984
Lundberg, C, Skoog, L, Cavenee, WK, Nordenskjold, M: Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13. Proc Natl Acad Sci USA 84: 2372–2376, 1987
Mukai, S, Dryja, TP: Loss of alleles at polymorphic loci on chromosome 2 in uveal melanoma. Cancer Genet Cytogenet 22: 45–56, 1986
Yokota, J, Wade, M, Simosato, Y, Terade, M, Sugimura, T: Loss of heterozygosity on chromosomes 3, 13 and 17 in small carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 84: 9252–9256, 1987
Weston, A, Willey, JC, MoDali, R, Sugimura, H, McDowell, EM, Resau, J, Light, B, Haugen, A, Mann, DL, Trump, BF: Differential DNA sequence deletions from chromosome 3, 11, 13 and 17 in squamous cell carcinoma, large cell carcinoma and adenocarcinoma of the lung. Proc Natl Acad Sci USA 86: 5099–5105, 1989
Zbar, B, Brauch, N, Talmadge, C, Linehan, M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327: 721–724, 1987
Seizinger, BR: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268–269, 1988
Solomaon, E, Voss, R, Hall, V, Bodmer, WF, Jass, JR, Jeffreys, AJ, Lucibello, FC, Patel, I, Rider, SH: Chromosome 5 alleles loss in human colorectal carcinoma. Nature 328: 616–618, 1987
Bodmer, WF, Bailey, CJ, Bodmer, J, Bussey, HJR, Ellis, A, Gorman, P, Lucibello, FC, Murday, VA, Rider, SH, Scambler, P, Sheer, D, Soloman, E, Spurr, NK: Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328: 614–616, 1987
Sandros, J, Mark, J, Happonen, RP, Stenman, G: Specificity of 6q-markers and other recurrent deviations in human malignant salivary gland tumors. Anticancer Research 8: 637–643, 1988
Diaz, MO, Ziemin, S, LeBeau, MM, Pitha, P, Smith, SD, Chilcote, RR, Rowley, JD: Homozygous deletion of the alpha- and betal interferon gene in human leukemia and derived cell lines. Proc Natl Acad Sci USA 85: 5259–5263, 1988
Simpson, NE: Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328: 528–530, 1987
James, CD, Carlbon, E, Dumanski, JP, Hansen, M, Nordenskjold, M, Collins, VP, Cavenee, WK: Clonal genomic alterations in glioma malignancy stage. Cancer Res 48: 5546–5551, 1988
Larsson, C, Skogseid, B, Oberg, K, Nakamura, Y, Nordenskjold, M: Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insuloma. Nature 332: 85–87, 1988
Orkin, SH, Goldman, DS, Sallan, SE: Development of homozygosity for chromosome 11p markers in Wilms' tumor. Nature 309: 179–181, 1984
Koufos, A, Hansen, MF, Copeland, NG, Jenkins, NA, Lampkin, BC, Cavenee, WK: Loss of heterogosity in three embryonal tumors suggest a common pathogenetic mechanism. Nature 316: 330–334, 1985
Fearon, ER, Feinberg, AP, Hamilton, SH, Vogelstein, B: Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318: 377–380, 1985
Koi, M, Morita, H, Yamada, H, Satoh, H, Barrett, JC, Oshimura, M: Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa. Mol Carcinog 2: 12–15, 1989
Lee, EY-HP, To, H, Shew, JY, Bookstein, R, Scully, P, Lee, WH: Inactivation of the retinoblastoma susceptibility gene in human breast cancer. Science 241: 218–244, 1988
Ali, IU, Lidereau, R, Theillet, C, Callahan, R: Reduction to homozygosity of genes on chromosome 11 in human neoplasia. Science 230: 185–188, 1987
Cavenee, WK, Dryja, RP, Philips, RA, Benedict, WF, Godbout, R, Gallie, BL, Murphree, AL, Strong, LC, White, RL: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305: 779–782, 1983
Hansen, MF, Koufos, A, Gallie, BL, Philips, RA, Fodstad, O, Brogger, A, Gedde-Dahl, T, Cavenee, WK: Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 82: 6216–6219, 1985
Friend, SH, Horowitz, JM, Gerber, MR, Wang, XF, Bogenmann, E, Li, FP, Weinberg, RA: Deletions of a DNA sequence in retinoblastoma and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 84: 9059–9063, 1987
Seizinger, BR, Martuza, RL, Gusella, JF: Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322: 644–646, 1986
Dumanski, JP, Carlbom, E, Collins, VP, Nordenskjold, M: Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci USA 84: 9375–9378, 1987
Rouleau, GA, Wertelecki, W, Hines, JL, Hobbs, WJ, Trofatter, JA, Seizinger, BR, Martuza, RL, Superneau, DW, Conneally, PM, Gusella, JF: Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329: 246–250, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chiao, P.J., Bischoff, F.Z., Strong, L.C. et al. The current state of oncogenes and cancer: Experimental approaches for analyzing oncogenetic events in human cancer. Cancer Metast Rev 9, 63–80 (1990). https://doi.org/10.1007/BF00047589
Issue Date:
DOI: https://doi.org/10.1007/BF00047589